Chest Pain and Spasms During Chemotherapy
Chest pain and spasms in patients receiving chemotherapy are most commonly caused by coronary vasospasm induced by specific chemotherapeutic agents, particularly 5-fluorouracil (5-FU) and capecitabine, which can occur even in patients without pre-existing coronary artery disease. 1
Primary Mechanisms and Causative Agents
Fluoropyrimidines (Most Common)
5-FU and capecitabine cause coronary vasospasm through direct effects on coronary arteries, leading to chest pain that can range from mild discomfort to severe ischemia with ST-segment changes and even myocardial infarction 1. This occurs in patients regardless of baseline cardiovascular risk factors 2, 3. The mechanism involves direct coronary artery spasm rather than atherosclerotic disease 2, 4.
Other Cardiotoxic Chemotherapy Agents
Additional agents associated with chest pain include:
- Platinum-based agents: Cisplatin 5
- Taxanes: Paclitaxel/docetaxel 5
- Anthracyclines: Doxorubicin (though primarily causes cardiomyopathy) 1
- Targeted therapies: Bevacizumab, sorafenib, carfilzomib 1
- Combination regimens: FOLFOX with bevacizumab 3
Secondary Cardiovascular Complications
Cancer patients have increased risk of:
- Arrhythmias: Atrial fibrillation, ventricular arrhythmias (10-fold increase after cancer diagnosis) 5
- Thrombotic events: Due to hypercoagulable state
- Metabolic derangements: Electrolyte abnormalities from nausea/vomiting/diarrhea 5
Immediate Management Algorithm
When Chest Pain Occurs During Infusion
Immediately withhold the offending drug until diagnostic workup is completed 1
Obtain serial ECGs to monitor for ST-segment changes or arrhythmias 1
Check troponin levels (preferably high-sensitivity) to rule out acute coronary syndrome 4
Institute anti-anginal therapy immediately:
Diagnostic Workup
Coronary evaluation is mandatory but the approach depends on acuity:
- Stable patients: Coronary CT angiography 4
- Unstable patients or positive troponins: Left heart catheterization 4
- Avoid exercise stress testing - it is contraindicated in active coronary spasm as it can exacerbate ischemia and trigger ventricular arrhythmias 4
Critical Pitfall
Do not assume atherosclerotic disease - these patients often have angiographically normal coronary arteries with vasospasm as the sole mechanism 2, 3, 7. Acetylcholine provocation testing during catheterization can confirm multi-vessel spasm 2.
Long-Term Management Strategy
Preemptive Approach for High-Risk Patients
For patients with pre-existing coronary artery disease or those restarting fluoropyrimidines, preemptive coronary vasodilators should be initiated before chemotherapy 1:
- Calcium-channel blockers (verapamil or dihydropyridines)
- Long-acting nitrates
Rechallenge Protocol
An alternative chemotherapy regimen without the offending drug is the preferred option 1. However, if rechallenge is necessary:
- Use standardized vasodilatory premedication protocol 4
- Close ECG monitoring during infusion 1
- Multidisciplinary cardio-oncology team involvement 4
Drug-Specific Discontinuation Guidelines
- 5-FU/capecitabine: Permanent discontinuation preferred; rechallenge only with intensive monitoring 1
- Sorafenib: Temporary or permanent discontinuation advised 1
- Bevacizumab: Prompt discontinuation; safety of restarting after arterial thrombotic events is unknown 1
- Carfilzomib: Prompt discontinuation when chest pain occurs during infusion 1
Special Considerations
Thrombocytopenia
If acute coronary syndrome occurs with chemotherapy-induced thrombocytopenia 1:
- Platelet >10,000: Aspirin can be given
- Platelet >30,000: Dual antiplatelet therapy possible with drug-eluting stents
- Use radial access, micropuncture kits, and closure devices for revascularization procedures
High-Risk Populations
Patients ≥75 years receiving carfilzomib require ischemic workup prior to starting treatment 1. Patients with stroke or MI within 12 months were excluded from bevacizumab trials, so safety in this population is unknown 1.